The global immune checkpoint inhibitors market was surpassed at USD 29,803.9 million in 2020 and is expected to hit around USD 1,40,890.23 million by 2030, growing at a CAGR of 16.80% from 2022 to 2030.
Key Findings Of The Study
Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present on tumor cells as they affect functioning of the immune system. Immune checkpoint inhibitor drugs block different checkpoint proteins including CTLA-4 (cytotoxic T lymphocyte associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death ligand 1). Immune checkpoint inhibitor targets checkpoint proteins and assists the immune system to recognize and attack cancer cells.
Immune checkpoint inhibitors are expected to exhibit significant market growth during the forecast period, owing to growth in demand for ideal therapeutics for treatment of cancer, favorable reimbursement policies provided by manufacturers & insurance providers in some countries, and surge in prevalence of cancer across the globe. The key factors driving growth of Immune Checkpoint Inhibitors market growth are attributed to increase in incidences of different forms of cancer, surge in awareness of checkpoint inhibitors for treatment of cancer, higher number of R&D studies, and surge in adoption of immune checkpoint inhibitor drugs. In addition, growth in geriatric population and technological advancements in screening & diagnosis of cancer further drives the market growth. However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.
The immune checkpoint inhibitors market is segmented on the basis of type, application, and region. On the basis of, the market is classified as CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. According application, it is categorized into lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Scope of The Report
Report Coverage | Details |
Market Size in 2020 | USD 29,803.9 million |
Revenue Forecast by 2030 | USD 1,40,890.23 million |
Growth rate from 2022 to 2030 | CAGR of 16.80% |
Base Year | 2020 |
Forecast Period | 2022 to 2030 |
Segmentation | type, application |
Companies Covered | AstraZeneca PLC; Bristol-Myers Squibb Company;Eli Lilly and Company (ARMO Biosciences.); GlaxoSmithKline PLC; F. Hoffmann-La Roche Ltd. (Genentech Inc.,); Sanofi; Merck & Co., Inc.; Merck KGaA (EMD Serono Inc.); BeiGene Ltd; Shanghai Jhunsi Biosciences Ltd. |
What is the Impact of COVID-19 on Immune Checkpoint Inhibitors Market?
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
The overall impact of COVID-19 remains negative on the immune checkpoint inhibitor market, owing to decline in number of cancer patients visits in hospitals and clinics for immune checkpoint inhibitor therapy (ICI) which lead to decline in the demand of Immune checkpoint inhibitors products. For instance, according to NCBI in 2020 around 50% of patient decrease is reported for cancer care in U.S. and overall cancer therapies are declined by 50% during COVID-19. Furthermore, WHO issued guidelines regarding the nonessential planned therapies such as for cancer and procedures based on the need of critical situations? The guidelines suggest to provide emergency services to patients who require urgent attention and postpone the therapies and surgery if not urgent, which lead to decline in the demand for immune check point products in the market.
In addition, owing to the outbreak most of the markets are experiencing a decline especially immune checkpoint inhibitors market. For instance, according to AstraZeneca plc, Opidivo (immune checkpoint inhibitor) registered a 5.6% decline in 2020 due to decline in no of cancer patients visit in clinics and hospitals during COVID-19 which led to decline in the demand for immune check point products in the market.
By Type Segment Review
By type, the immune checkpoint inhibitors market is divided into CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. The PD-1 inhibitor segment was the major revenue contributor in 2020, and is anticipated to continue this trend during the forecast period, owing due to increase in adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally. On the other side, the demand for PD-L1 inhibitor is projected to exhibit the fastest immune checkpoint inhibitors market growth during the forecast period, owing to rise in use of durvalumab & avelumab and surge in R&D studies for PD-L1 inhibitors.
By Application Segment Review
By application, the immune checkpoint inhibitors market is classified as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due owing to increase in use of immune checkpoint inhibitors for the treatment of lung cancer and surge in prevalence of lung cancer globally. However, the bladder cancer segment is projected to show fastest growth during the forecast period, due owing to increase in incidences of bladder cancer.
By Region segment review
By region, the Immune checkpoint inhibitors market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. The research activities for immune checkpoints inhibitors are soaring in North America due to significant infrastructure for developmental research, availability of substantial research funds and growing government initiatives towards immune checkpoint inhibitors are anticipated to drive the market growth.
This report provides comprehensive competitive analysis and profiles of prominent market players such as Key players operating in the global immune checkpoint inhibitors market are, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.) GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd.
Key Benefits for Stakeholders
KEY PLAYERS
Market Segments
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Immune Checkpoint Inhibitors Market
5.1. COVID-19 Landscape: Immune Checkpoint Inhibitors Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Immune Checkpoint Inhibitors Market, By Type
8.1. Immune Checkpoint Inhibitors Market, by Type, 2022-2030
8.1.1. CTLA-4 Inhibitor
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. PD-1 Inhibitor
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. PD-L1 Inhibitor
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Immune Checkpoint Inhibitors Market, By Application
9.1. Immune Checkpoint Inhibitors Market, by Application, 2022-2030
9.1.1. Lung Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bladder Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Melanoma
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Hodgkin lymphoma
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Immune Checkpoint Inhibitors Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
Chapter 11. Company Profiles
11.1. AstraZeneca PLC
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Bristol-Myers Squibb Company
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Eli Lilly and Company (ARMO Biosciences.)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GlaxoSmithKline PLC
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd. (Genentech Inc.,)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sanofi
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Merck KGaA (EMD Serono Inc.)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. BeiGene Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Shanghai Jhunsi Biosciences Ltd.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms